EFFICACY AND SAFETY of aflibercept ASSOCIATED WITH A FOLFIRI CHEMOTHERAPY IN 1ST LINE TREATMENT OF PATIENTS SUFFERING FROM METASTATIC COLORECTAL CANCER Phase II - single arm - multicenter

Primary objectives: To evaluate the patients rate without progression or death at 6 months (RECIST version 1.1) according to the investigator Primary endpoints: The main end point is the patients rate without progression or death at 6 months according to the investigator.The progression is defined by:• progression assessed by TDM (RECIST version 1.1)• any cause of death首要研究目标：评估经研究者评估、符合实体瘤疗效评价标准1.1版（RECIST version 1.1）的患者在6个月时无疾病进展或死亡的比例。 主要研究终点：主要研究终点为经研究者评估、符合实体瘤疗效评价标准1.1版（RECIST version 1.1）的患者在6个月时无疾病进展或死亡的比例。疾病进展的定义如下： • 经肿瘤动态监测（TDM）评估的、符合RECIST 1.1版标准的疾病进展 • 任何原因导致的死亡